Aging and Disease

Engineering the Future of Longevity R&D: The Case for AI-Driven, Integrated Biotechnology Ecosystems

Follow

Abstract

The escalating cost, extended timelines, and low success rates in pharmaceutical research demand a rethinking of biotechnology R&D infrastructure to more efficiently discover and deliver novel therapeutics to an increasingly aging population. We introduce the concept of the AI-Integrated Biotechnology Hub, a purpose-built research ecosystem uniting residential, commercial, clinical, and research facilities under a central, AI-driven operating system. The hub functions as a multi-sided platform that unites health data collection, smart living environments, and federated learning to enable secure, privacy-preserving biomedical and longevity research. By integrating real estate, biotechnology facilities, research hospitals, and community services, the model maximizes data utility, accelerates drug discovery, and enhances resident well-being. Transparency, accountability, and ethical stewardship are critical pillars of governance, enacted through dynamic consent, data trusts, and multi-stakeholder oversight. Designed to be scalable across urban and vertical architectures, this paradigm represents a potential approach that may enable more efficient research workflows to improve healthspan, foster innovation, and reshape the economics of global drug development.

The paper

Insilico Medicine (United States); Silver Dart Capital

Aging and Disease, 11 Dec 2025

doi.org/10.14336/ad.2025.1313PubMed 41400581